SL Science Holding Limited SLBT
Set alert
1.20 USD +0.03 +2.56%
At close
1.27 +0.07 +5.83%
Pre-market · Nov 2, 7:21 AM ET
1.16 Day range 1.29
1.02 52-week range 14.50
- YTD
- -88.63%
- 1 year
- -88.45%
- Open
- 1.16
- Prev close
- 1.17
- Mkt cap
- 672.91M
- Vol
- 26.62K
- Avg vol
- 69.51K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.16
- High
- 1.29
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.36
- Inst. own
- 0.29%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.59
- 200-d avg
- 7.18
- 1y target
- 0.00
6M chart
Signals (27)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Sep 29, 2026 | 1 month ago |
| RSI: Oversold | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 27, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 7, 2026 | 3 months ago |
| SMA: Bearish | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | Jun 16, 2026 | 4 months ago |
| SMA: Bearish | Jun 12, 2026 | 4 months ago |
| SMA: Bearish | Jun 12, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 12, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bearish | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 14, 2026 | 5 months ago |
| SMA: Bullish | May 13, 2026 | 5 months ago |
| SMA: Bearish | May 12, 2026 | 5 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
Key statistics
- Market cap
- 1.03B
- Enterprise value
- 4.03M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 313.81
- Price / book
- 1.42
- EPS (TTM)
- -0.01
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -72.46%
- Revenue (TTM)
- 3.27M
- Revenue growth
- -7.60%
- Free cash flow
- 0
- Total cash
- 3.37M
- Total debt
- 305.67K
- Return on equity
- 0.00%
- Shares outstanding
- 560.76M
- Short % of float
- 0.01%
- 50-day average
- 2.59
- 200-day average
- 7.18
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
SLBT Revenue — quarterly 2.20M
SLBT Net income — quarterly -5.13M
SLBT EPS — quarterly 0.099
About SL Science Holding Limited
SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Taiwan
- Website
- sl-bio.com
News
- SL Science Holding H1 Sales $1.387M Up From $1.129M YoY
- SL Science Holding Limited Reports First Half 2026 Financial Results
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NetApp, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
- Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
- SL Science Highlighted The Filing Of A New Drug Master File With The U.S. FDA Covering Exosomes Derived From Gamma Delta T Cells
- SL Science Announces Publication Of Peer-Reviewed Article In 'Biomedicines' Outlining A Rigorous Development Framework For γδ T Cell Therapy In Glioblastoma
Your note
Sign in to keep a note on SLBT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.03% | 193,404 | 353.93K | Jun 29, 2026 |
| L1 Global Manager Pty Ltd | 0.03% | 150,000 | 274.50K | Jun 29, 2026 |
| RiverNorth Capital Management, LLC | 0.02% | 130,000 | 237.90K | Jun 29, 2026 |
| SkyView Investment Advisors, LLC | 0.01% | 42,042 | 76.94K | Jun 29, 2026 |
| Lynx Capital Group Ltd /adv | 0.00% | 17,096 | 31.29K | Jun 29, 2026 |
| UBS Group AG | 0.00% | 12,515 | 22.90K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.06% | 338,215 | 618.93K | Jul 30, 2026 |